ALICE

Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer. NBCG16, PI: Jon Amund Kyte.

EMIT1

EMIT: Establishment of Molecular profiling for Individual Treatment decisions in Early Breast Cancer. PI: Bjørn Naume.

DBCG RT NATURAL

DGBC NATURAL studien (NBCG21). Delbryst versus ingen bestråling til kvinder ≥ 60 år opereret med brystbevarelse for tidlig brystkræft, et klinisk kontrolleret randomiseret fase III studium.

NEOLETEXE

Presurgical treatment with letrozole and exemestane in postmenopausal patients with ER-positive, locally advanced breast cancer: an intra-patient, cross-over trial. PI: Jürgen Geisler.

OPTIMA

OPTIMA (EMIT2). Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis. Bruk av Prosigna test til adjuvant behandlingsbeslutning. PI: Bjørn Naume.

Skagen Trial I

Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost. PI: Ingvil Mjaaland.

EPIK-B3

A phase III, multicenter, randomized, double blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphate and tensin homolog protein (PTEN) loss without PIK3CA mutation. PI Norge: Olav Engebråten, OUS